Organovo Advances in 3D Bioprinting and Stock Performance

Author

Reads 3K

Tissue culture plants in glass bottles, showcasing laboratory methods in botany.
Credit: pexels.com, Tissue culture plants in glass bottles, showcasing laboratory methods in botany.

Organovo has made significant advancements in 3D bioprinting, a technology that enables the creation of functional human tissues and organs. This breakthrough has the potential to revolutionize the field of regenerative medicine.

The company's innovative approach has allowed them to develop functional liver tissue that can be used for testing the safety of new drugs. This is a major step forward in the development of more effective and safer medications.

Organovo's stock performance has been impressive, with the company's shares increasing in value over time. Their commitment to research and development has helped them stay ahead of the competition.

The company's focus on 3D bioprinting has also enabled them to create more accurate models of human diseases, which can be used to test potential treatments.

Take a look at this: Tucows

Company Information

Organovo is a San Diego-based company that specializes in developing 3D-bioprinted tissues and organs for research and medical applications.

Their technology uses a process called biofabrication to create complex tissue structures that mimic the properties of native tissues.

Organovo was founded in 2008 by Keith Murphy and Gabor Forgacs.

Their headquarters is located in San Diego, California.

The company has developed a range of 3D-bioprinted tissues, including liver, kidney, and lung tissues, which are used in research and development applications.

Recommended read: San Diego Gas & Electric

Financials

Credit: youtube.com, Organovo Rings the NASDAQ Bell - October 18, 2016

Organovo Holdings has reported a profit margin of $75K in June 2023, which is a significant improvement from the previous quarter. This indicates that the company is making progress in its financial performance.

The company's financial statements show a net loss of $-4.02M in June 2023, which is a substantial decrease from the previous quarter. However, this is not surprising given the company's focus on research and development.

Here is a breakdown of Organovo Holdings' financial performance over the past year:

In its Form 10-Q report for the third quarter of fiscal year 2025, Organovo Holdings reported a net loss of $3.447 million, which is a slight improvement from the previous year. This is primarily due to cost management and reduced expenses.

Financial Statements

Organovo Holdings, Inc. released its Form 10-Q report for the third quarter of fiscal year 2025, providing a comprehensive overview of the company's financial performance and key business activities.

Credit: youtube.com, FINANCIAL STATEMENTS: all the basics in 8 MINS!

The report highlights a slight increase in total revenues to $0.024 million, mainly due to higher royalty and product revenues.

A decrease in operating loss is also noted, driven by reduced selling, general, and administrative expenses.

The net loss decreased to $(3.447) million, a slight improvement from the previous year's net loss, primarily due to cost management and reduced expenses.

Organovo Holdings' net loss per common share—basic and diluted—is $(0.19), showing an improvement in per-share loss compared to the previous year.

The company's financial statements show a profit margin of -72080% for December 2023, indicating a significant loss.

Here's a breakdown of Organovo Holdings' financial statements for the past year:

These financial statements provide valuable insights into Organovo Holdings' performance and help investors make informed decisions about the company's future prospects.

Earnings Call Transcripts

Earnings Call Transcripts are a valuable resource for investors and analysts to stay up-to-date on a company's financial performance.

Organovo Holdings, a biotech company, has made their Earnings Call Transcripts publicly available.

Credit: youtube.com, Earnings Calls and Presentations

The transcripts cover various quarters, with the most recent one being Q4 2019, which was released on May 23, 2019.

Here's a breakdown of the available Earnings Call Transcripts for Organovo Holdings:

These transcripts offer a wealth of information, providing a detailed look at the company's financial performance and management's perspective on the future.

Stock Performance

Organovo's stock price can be quite volatile. It soared 49.7% in one week due to a licensing agreement with a Swedish company that brought in much-needed cash.

The company's stock performance can be influenced by significant events. Organovo's stock fell as much as 28.4% on a day when the company reported its fiscal fourth-quarter and full-year 2018 results.

Stock Rise 49.7% This Week

Organovo Holdings, Inc. stock soared 49.7% this week.

The company's licensing agreement with a Swedish company was a major factor in this significant stock rise.

This agreement brought in much-needed cash for Organovo, which likely helped boost investor confidence and drive up the stock price.

The influx of cash from the licensing agreement provided Organovo with the financial resources to invest in its business and potentially drive future growth.

Stock Plummets 28.4%

A modern abstract 3D render with blue geometric shapes and a sphere.
Credit: pexels.com, A modern abstract 3D render with blue geometric shapes and a sphere.

Organovo Holdings stock took a significant hit, dropping as much as 28.4% in a single day.

The company reported fiscal fourth-quarter and full-year 2018 results, which likely contributed to the decline.

Events and Conferences

Organovo is participating in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022.

Executive Chairman Keith Murphy will represent the company at this event, aiming to advance drug development for Crohn's Disease.

The company has recently established its first 3D tissue model, a significant step towards this goal.

Participate in H.C. Wainwright Global Investment Conference

Organovo Holdings will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The conference is a significant event for investors to learn about the company's innovative 3D tissue models for drug development.

Keith Murphy, the Executive Chairman of Organovo, will represent the company at the conference. This is a great opportunity for investors to hear from the company's leadership and learn about their latest developments.

The corporate presentation will be webcast on September 12, 2022, at 7:00 AM ET. You can access the archived presentation on Organovo's website for 90 days if you miss the live broadcast.

Postpones Annual Stockholders Meeting

Credit: youtube.com, Can We Postpone Our Annual Shareholders Meeting?

Organovo Holdings (ONVO) recently postponed its 2022 Annual Meeting from September 7 to October 12, 2022, at 9:00 AM PT.

The company made this decision after receiving less than 35% of proxies by the previous record date, July 15, 2022.

The new record date for the meeting is set for September 7, 2022, and the meeting will be conducted virtually to enhance stockholder participation.

An amended proxy statement will be filed promptly with the SEC, providing updated information regarding the meeting.

3D Bioprinting

3D bioprinting is a complex process that involves creating customized 3D human tissues for drug development.

Several technologies are used for 3D bioprinting, including photolithography, magnetic 3D bioprinting, stereolithography, and direct cell extrusion. These methods require a physical biopsy of an organ, which is then used to isolate and multiply certain cells.

These cells are mixed with a liquefied material that provides oxygen and other nutrients to keep them alive outside of the human body. The mixture is then placed in a printer cartridge and structured using the patient's medical scans.

Credit: youtube.com, The Bioprinting Process

Organovo has successfully created a 3D tissue model for Crohn's disease, demonstrating key aspects of patient biology. This model is positioned to identify therapeutics for the disease.

Organovo has also partnered with BICO, granting them a broad license to its foundational patents in 3D bioprinting. This agreement resolves prior legal disputes between the two companies regarding patent infringement.

3D Bioprinting Process

The 3D bioprinting process involves creating a physical model of an organ by printing cells layer by layer. This process requires a physical biopsy of an organ, which is then used to isolate and multiply certain cells.

These cells are mixed with a liquefied material that provides oxygen and other nutrients to keep them alive outside of the human body. The mixture is then placed in a printer cartridge and structured using the patient's medical scans.

There are several methods used for 3D bioprinting of cells, including photolithography, magnetic 3D bioprinting, stereolithography, and direct cell extrusion. Each method has its own strengths and weaknesses, but they all require a biopsy to start the process.

The goal of 3D bioprinting is to create a model that accurately represents the patient's biology, which can be used to identify potential therapeutics. This is exactly what Organovo Holdings, Inc. achieved with their 3D tissue model for Crohn's disease, which demonstrates key aspects of patient biology.

Credit: youtube.com, 3D Bioprinting and Bioinks: Creating Organs from Scratch (ft. Dr. Itedale Namro Redwan) | Ep. 30

BICO and CELLINK have reached a licensing agreement on bioprinting patents with Organovo.

This agreement grants BICO a broad license to Organovo's foundational patents in 3D bioprinting, resolving prior legal disputes between the two companies.

Organovo's technology aims to create customized 3D human tissues for drug development, focusing on complex disease models.

The company views this partnership as a significant move to broaden the impact of its bioprinting technology and support the growth of BICO's product lines.

This partnership will allow BICO to expand its product lines using Organovo's bioprinting technology.

Organovo's technology has the potential to revolutionize the field of drug development by providing customized 3D human tissues for testing.

BICO and Cellink have reached a patent licensing agreement with Organovo, a significant step in resolving previous legal disputes over potential patent infringements. This collaboration marks a major milestone in the development of 3D bioprinting technology.

The agreement grants BICO a broad license to Organovo's foundational patents in 3D bioprinting, allowing them to enhance their product lines and make further advancements in the field. Organovo's technology has the potential to create customized 3D human tissues for drug development, focusing on complex disease models.

Under this partnership, all civil actions regarding patent disputes are dismissed, and the agreement is seen as a significant move to broaden the impact of Organovo's bioprinting technology and support the growth of BICO's product lines.

Operations and Management

Credit: youtube.com, Company Profile: Organovo

Organovo has made significant strides in its operations. In 2015, they signed an agreement with L'Oreal to provide 3D printed human skin for testing cosmetic products.

This collaboration demonstrates Organovo's expertise in producing high-quality, functional human tissue for a variety of applications. Their technology has the potential to revolutionize the way companies test their products.

Employees

Organovo Holdings has experienced fluctuations in its employee count over the past year.

In August 2023, the company had 15 employees.

The employee count remained steady at 23 from September to December 2023, and then again from January to June 2024.

However, the number of employees dropped to 18 in March 2024 and stayed at that level for the next three months.

By July 2024, the employee count had decreased further to 12.

Operations

Organovo has a partnership with L'Oreal to provide 3D printed human skin for testing cosmetic products.

In 2015, they signed an agreement to supply this technology.

Investment and Funding

Credit: youtube.com, Organovo (ONVO): Stock Analysis | Is it a Buy? | Feb 2025 | Trending Investment Insights

Organovo went public on OTC markets in 2012 via a reverse merger with shell company Real Estate Restoration and Rental, Inc. In July 2013, the company uplisted to the NYSE MKT.

The company hit a market cap high of $700m in 2013, a significant milestone in its growth. Organovo had 22.4 million shares outstanding at the time of listing.

In 2020, the number of shares outstanding had increased to over 130 million, a substantial increase from the initial 22.4 million.

Financing

Financing can be a complex and confusing topic for investors. Organovo went public on OTC markets in 2012 via a reverse merger with shell company Real Estate Restoration and Rental, Inc.

This move allowed the company to access new funding sources and increase its visibility in the market. In July 2013, Organovo uplisted to the NYSE MKT, a significant milestone in its growth trajectory.

The company's market cap reached a high of $700m in 2013, a testament to its successful funding efforts. At the time of listing, Organovo had 22.4 million shares outstanding, a relatively small number compared to its later growth.

By 2020, the number of shares outstanding had increased to over 130 million, a significant increase in just a few years. This expansion of the company's equity base allowed Organovo to raise more capital and pursue new opportunities.

Alternative Data

Credit: youtube.com, The Power of Alternative Data in Investing

Alternative data is a game-changer in the world of investment and funding. It's a type of data that's not typically found in traditional financial statements, but can provide valuable insights into a company's performance and potential.

Alternative data can include everything from social media activity to online search trends. This type of data can be used to identify trends and patterns that may not be apparent from traditional financial data.

For example, a company that's experiencing a surge in social media activity may be a good investment opportunity. This is because social media activity can be a strong indicator of a company's popularity and potential for growth.

Alternative data can also be used to identify potential risks and challenges facing a company. By analyzing online reviews and complaints, investors can get a better sense of a company's customer satisfaction and potential for future growth.

In some cases, alternative data can even be used to identify new business opportunities. For instance, a company that's experiencing a high volume of online searches for a particular product or service may be a good opportunity for investment.

Frequently Asked Questions

Is Organovo publicly traded?

Yes, Organovo is publicly traded. Its common stock trades on the NASDAQ Stock Market under the ticker symbol ONVO.

Alfred Blanda

Senior Writer

Alfred Blanda has carved out a niche for himself in the realm of banking information, offering readers clear, concise, and comprehensive insights into the financial sector. His articles are known for their depth and clarity, making complex financial concepts accessible to a wide audience. With a keen eye for detail and a passion for educating, Blanda continues to be a trusted voice in financial journalism.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.